tbuckley/cabot-search huggingface dataset:
NIMG-77. IMPACT OF POST-SURGICAL ENHANCING TUMOR VOLUME AND T2/FLAIR VOLUME ON THE SURVIVAL IMPACT OF BEVACIZUMAB IN NRG ONCOLOGY/RTOG 0825
Authors: Michael Vogelbaum, Kristin Swanson, Peixin Zhang, Daniel Cahill, Andrea Hawkins-Daarud, Mark R Gilbert, Gustavo De Leon, Cassandra Rickertsen, Lauren Kunkel, Wenyin Shi, Marta Penas-Prado, Emad Youssef, Hui-Kuo Shu, Merideth Wendland, John Suh, John Keech, Steven Howard, Vesna Kaluza, Minhee Won, Minesh P Mehta
Journal: Neuro-Oncology (2017)

RTOG 0825 randomized 621 newly-diagnosed glioblastoma patients to treatment with or without bevacizumab, in addition to standard-of-care radiotherapy plus concurrent/adjuvant temozolomide. No significant difference was seen between the treatment arms in overall survival (OS), and the difference in progression free survival (PFS) did not meet the pre-defined statistical margin. We evaluated the impact of post-surgical MRI-determined residual tumor on outcomes. 431 (69.4%) patients had post-operative T1 MRIs (with and without gadolinium) and 517 (83.2%) had T2 or FLAIR images. Volumetric segmentation was performed to calculate residual enhancing (T1Gd-T1) volume (rEV) and T2/FLAIR volume (rT2FV). Multivariable analyses were performed using Cox models with pretreatment characteristics and treatment as covariates. Median post-operative, pre-treatment rEV was 2.8 cc (range 0.0-79.6 cc) and rT2FV volume was 52.3 cc (0.0-279. 8 cc). Neither age nor MGMT methylation were predictors of rEV or rT2FV. Ninety-four (21.8%) patients had an imaging-complete resection of enhancing tumor (rEV=0.0). We did not detect a significant difference in OS or PFS for an imaging-complete resection. Notably, however, a rEV <= 2.8 cc was associated with better OS (HR=1.37, p=0.008 Log-rank) and PFS (HR=1.25, p=0.04 Log-rank). rT2FV had no detectable impact on OS or PFS, but there were significant interactions affecting outcomes between treatment arms and rT2FV. Patients with a less than median rT2FV had improved PFS with bevacizumab (HR=0.64, p=0.001). Surprisingly, patients with a higher than median rT2FV had poorer OS with bevacizumab (HR=1.42, p=0.02). These prospective data demonstrate the benefits associated with minimizing residual contrast-enhancing tumor in glioblastoma. MGMT status did not appear to independently determine residual tumor volume after surgery. Finally, bevacizumab appears to provide PFS benefit in patients with smaller rT2FV, and diminishes OS in patients with larger rT2FV. Supported by U10CA180868 (NRG Oncology Operations), U10CA180822 (NRG Oncology SDMC) from the NCI and Genentech.
Occurrence of ultrasound-detected symptomatic and asymptomatic central vein catheter-related thrombosis in pediatric oncology patients
Authors: L. Gandini, P. Previtali, S. Paladini, M.C. Allemano, C. Morosi, E. Tagliabue, D. Codazzi, M. Massimino
Journal: Annals of Oncology (2017)
NCMP-07. LAMOTRIGINE EFFICACY OF SEIZURE CONTROL AND TOLERABILITY ON PATIENTS WITH BRAIN TUMORS: A RETROSPECTIVE REVIEW
Authors: Wendy Sherman, Abby Rogers
Journal: Neuro-Oncology (2017)

Patients with brain tumors have a high incidence of seizures—arising in 40-60% of patients. Antiepileptic drug therapy is indicated for life following the initial seizure. However, adverse effects, drug interactions, and tumor growth complicate the choice of antiepileptic medication. Lamotrigine is a well-tolerated antiepileptic medication with potential advantageous side effects including increased alertness and mood stability, both potentially advantageous in this patient population. Currently, the efficacy of lamotrigine is unknown in brain tumor patients. Our objective was to evaluate lamotrigine’s effect on seizure frequency, tolerability, and depression for glioma patients. A retrospective chart review was performed on all glioma patients age 18 years and older treated with lamotrigine between January 2010 and January 2017 at Spectrum Health. Study data were collected and managed using REDCap electronic data capture tools hosted at Spectrum Health. Our results show that recorded seizure frequency did not increase following 6 months of lamotrigine; one patient experienced decreased seizure frequency. Tolerability was mixed with 4 out 17 (23.5%) documented patients discontinuing treatment due to toxicities which included anxiety (2), tremors (1) and rash (1). Although not statistically significant, median depression and interquartile range of PHQ-9 scores improved from 6 [5] to 0 [11] after 6 months of lamotrigine treatment (p-value of 0.3086) These results suggest efficacy of lamotrigine in seizure control and depression, but tolerability was mixed. This retrospective review supports future prospective studies of lamotrigine in brain tumor patients.
HOUT-03. SIGNIFICANCE OF COMORBIDITY INDEX IN ELDERLY PATIENTS WITH GLIOBLASTOMA
Authors: Masaki Okada, Daisuke Ogawa, Tetsuhiro Hatakeyama, Aya Shinomiya, Keisuke Miyake, Takashi Tamiya
Journal: Neuro-Oncology (2017)

Comorbidity is a common problem in the treatment of elderly patients, but there is no standard method of the evaluation in glioblastoma patients. Charlson comorbidity index (CCI) has been proposed as the prognostic index associating with the prognosis of various diseases. CCI is calculated by weighting against comorbidities such as congestive heart failure, COPD, diabetes, liver renal disease, and cancer-bearing condition. We examined the relationship between CCI and prognosis of elderly patients with glioblastoma. 28 patients over 70 years treated at our hospital from Dec.2006 to Dec.2016. 16 males and 12 females. Average age 76.8 years (70-86 years old). Relationship to overall survival (OS) was examined focusing on the age, CCI at hospitalization, Karnofsky Performance Status (KPS), surgery, radiotherapy (standard and hypofractionated), temozolomide-based chemotherapy. There was no significant correlation between age and CCI, but a weak negative correlation between KPS and CCI (r = - 0.302). Mean OS was 13.5 months in the resection group, 8.6 m in the biopsy group and 9.2 months in the non-surgery group. OS was longer in the resection group, but no difference in CCI. No significant difference in OS between standard radiotherapy with TMZ and hypofractionated radiotherapy with TMZ (13.2 m vs 11.5 m), with no concern to CCI. OS tended to be shorter in the high CCI group (8.6 m vs 14.5 m). The presence of comorbidities is one of the factors related to prognosis, and glioblastoma affecting the brain is in a disadvantageous condition due to cognitive dysfunction and paralysis. Since surgical excision and radiation chemotherapy lead to improvement in prognosis even in the elderly, it is important to complete the treatment paying maximum attention to the management of comorbidities. CCI would be useful to evaluate comorbidities. Further examination is needed in large cohort.
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial
Authors: Ivo N van Schaik, Vera Bril, Nan van Geloven, Hans-Peter Hartung, Richard A Lewis, Gen Sobue, John-Philip Lawo, Michaela Praus, Orell Mielke, Billie L Durn, David R Cornblath, Ingemar S J Merkies, A. Sabet, K. George, L. Roberts, R. Carne, S. Blum, R. Henderson, P. Van Damme, J. Demeestere, S. Larue, C. D'Amour, V. Bril, A. Breiner, P. Kunc, M. Valis, J. Sussova, T. Kalous, R. Talab, M. Bednar, T. Toomsoo, I. Rubanovits, K. Gross-Paju, U. Sorro, M. Saarela, M. Auranen, J. Pouget, S. Attarian, G. Le Masson, A. Wielanek-Bachelet, C. Desnuelle, E. Delmont, P. Clavelou, D. Aufauvre, J. Schmidt, J. Zschuentssch, C. Sommer, D. Kramer, O. Hoffmann, C. Goerlitz, J. Haas, M. Chatzopoulos, R. Yoon, R. Gold, P. Berlit, A. Jaspert-Grehl, D. Liebetanz, A. Kutschenko, M. Stangel, C. Trebst, P. Baum, F. Bergh, J. Klehmet, A. Meisel, F. Klostermann, J. Oechtering, H. Lehmann, M. Schroeter, T. Hagenacker, D. Mueller, A. Sperfeld, F. Bethke, V. Drory, A. Algom, D. Yarnitsky, B. Murinson, A. Di Muzio, F. Ciccocioppo, S. Sorbi, S. Mata, A. Schenone, M. Grandis, G. Lauria, D. Cazzato, G. Antonini, S. Morino, D. Cocito, M. Zibetti, T. Yokota, T. Ohkubo, T. Kanda, M. Kawai, K. Kaida, H. Onoue, S. Kuwabara, M. Mori, M. Iijima, K. Ohyama, M. Baba, M. Tomiyama, K. Nishiyama, T. Akutsu, K. Yokoyama, K. Kanai, I.N. van Schaik, F. Eftimov, N.C. Notermans, N. Visser, C. Faber, J. Hoeijmakers, K. Rejdak, U. Chyrchel-Paszkiewicz, C. Casanovas Pons, M. Alberti Aguiló, J. Gamez, M. Figueras, C. Marquez Infante, S. Benitez Rivero, M. Lunn, J. Morrow, D. Gosal, T. Lavin, I. Melamed, A. Testori, S. Ajroud-Driss, D. Menichella, E. Simpson, E. Chi-Ho Lai, M. Dimachkie, R.J. Barohn, S. Beydoun, H. Johl, D. Lange, A. Shtilbans, S. Muley, S. Ladha, M. Freimer, J. Kissel, N. Latov, R. Chin, E. Ubogu, S. Mumfrey, T. Rao, P. MacDonald, K. Sharma, G. Gonzalez, J. Allen, D. Walk, L. Hobson-Webb, K. Gable
Journal: The Lancet Neurology (2017)
P2.01-051 Randomized Study of Pemetrexed Versus Erlotinib as Maintenance Therapy in Metastatic /Locally Advanced EGFR Mutation Negative NSCLC
Authors: A. Joshi, V. Noronha, V. Patil, M. Sharma, C. Vora, V. Talreja, S. Goud, S. More, S. Shah, A. Mahajan, A. Janu, R. Kaushal, K. Prabhash
Journal: Journal of Thoracic Oncology (2017)
Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis
Authors: Teresa García‐Lezana, Imma Raurell, Miren Bravo, Manuel Torres‐Arauz, María Teresa Salcedo, Alba Santiago, Andreu Schoenenberger, Chaysavanh Manichanh, Joan Genescà, María Martell, Salvador Augustin
Journal: Hepatology (2017)

Portal hypertension (PH) drives most of the clinical complications in chronic liver diseases. However, its progression in nonalcoholic steatohepatitis (NASH) and its association with the intestinal microbiota (IM) have been scarcely studied. Our aim was to investigate the role of the IM in the mechanisms leading to PH in early NASH. The experimental design was divided in two stages. In stage 1, Sprague‐Dawley rats were fed for 8 weeks a high‐fat, high‐glucose/fructose diet (HFGFD) or a control diet/water (CD). Representative rats were selected as IM donors for stage 2. In stage 2, additional HFGFD and CD rats underwent intestinal decontamination, followed by IM transplantation with feces from opposite‐diet donors (heterologous transplant) or autologous fecal transplant (as controls), generating four groups: CD‐autotransplanted, CD‐transplanted, HFGFD‐autotransplanted, HFGFD‐transplanted. After IM transplantation, the original diet was maintained for 12‐14 days until death. HFGFD rats developed obesity, insulin resistance, NASH without fibrosis but with PH, intrahepatic endothelial dysfunction, and IM dysbiosis. In HFGFD rats, transplantation with feces from CD donors caused a significant reduction of PH to levels comparable to CD without significant changes in NASH histology. The reduction in PH was due to a 31% decrease of intrahepatic vascular resistance compared to the HFGFD‐autotransplanted group (P < 0.05). This effect occurs through restoration of the sensitivity to insulin of the hepatic protein kinase B–dependent endothelial nitric oxide synthase signaling pathway. Conclusion: The IM exerts a direct influence in the development of PH in rats with diet‐induced NASH and dysbiosis; PH, insulin resistance, and endothelial dysfunction revert when a healthy IM is restored. (Hepatology 2018;67:1485‐1498)
P3.08-006 Treatment Response and Survival Outcomes Are Associated with Histologic Type in Non-Small Cell Lung Cancer Treated with Trimodal Treatment
Authors: H.K. Kim, S. Shin, J.H. Cho, Y.S. Choi, J.I. Zo, Y.M. Shim, K. Park, M. Ahn, J.S. Ahn, S. Lee, J. Sun, Y.C. Ahn, H.R. Pyo, J.M. Noh, J. Han, J. Kim
Journal: Journal of Thoracic Oncology (2017)
P3.01-039 Sequential Afatinib-Osimertinib Therapy in EGFR Mutation-Positive (EGFRm+) NSCLC: Analysis of Time on Treatment and OS
Authors: K. Park, E. Tan, K. O’Byrne, L. Zhang, M. Boyer, T. Mok, V. Hirsh, J.C. Yang, M. Schuler, N. Yamamoto, L. Sequist, Y. Wu, C. Zhou, E. Ehrnrooth, A. Märten, W. Tang, L. Paz-Ares
Journal: Journal of Thoracic Oncology (2017)
P3.02b-107 Efficacy of Afatinib and Gefitinib in Lung Adenocarcinoma with EGFR Gene Mutation as 2nd or 3rd Line Treatment
Authors: Marisol Arroyo Hernandez, Jerónimo Rodríguez Cid, Jorge Alatorre Alexander, José Escobar-Penagos, Julio Garibay-Diaz
Journal: Journal of Thoracic Oncology (2017)
Tendências da asma na Suíça: a rede de vigilância sentinela suiça, 1988-1996
Authors: U Bollag, J Cloetta, J Oberreich, W J Paget
Journal: Eurosurveillance (1999)

A asma e um problema de saude publica importante, a nivel mundial, entre criancas e adultos. Estudos realizados em populacoes sugerem que a prevalencia, quer de asma expiratoria, quer de asma diagnosticada aumentaram ao longo do tempo (1). Parte deste aparente aumento pode ter ocorrido como resultado de uma maior consciencializacao do publico para a asma, aumentando a tendencia dos pais para procurarem cuidados medicos para a asma, logo que os seus filhos se apresentam com uma respiracao sibilante. A tosse, como principal sintoma de doenca respiratoria viral, pode ser atribuida a asma quando, na realidade, faz parte do processo infeccioso e representa uma constricao nao especifica da arvore bronquica (2).
P3.14-012 Risk of Developing Pneumonitis Increases in Patients Receiving Immunotherapy with a History of Lung Irradiation
Authors: F. Barron, L. Ramirez-Tirado, O. Macedo-Pérez, M. Arroyo Hernandez, D. Flores-Estrada, Y. Dorantes, F. Maldonado, O. Arrieta
Journal: Journal of Thoracic Oncology (2017)
Subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase 3 study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC)
Authors: M. Reck, L. Paz-Ares, M. Pérol, M. Johnson, N. Pennell, S. Novello, F. Cappuzzo, P. Bidoli, A. Zimmermann, P. Lee, A. Sashegyi, R. Varea Menendez
Journal: Annals of Oncology (2017)
NIMG-65. CD49d CORRELATED WITH APPARENT DIFFUSION COEFFICIENT AS A PROMISING BIOMARKER FOR PROGNOSIS PREDICTION OF GLIOBLASTOMA: RADIOGENOMICS STUDY
Authors: Hyejin Jeon, Hye Rim Cho, Chul-kee Park, Sung-Hye Park, Nisha Kumarir, Nishant Thakur, Jooyeon Chung, Seung Hong Choi
Journal: Neuro-Oncology (2017)

Glioblastoma multiforme (GBM) is one of the most lethal cancer with only minimally prolonged survival by current standard-of-care treatment and no definitive cures. Accordingly, targeting immune cells in GBM as the alternative therapeutic strategy is emerging. Recently, radiogenomics was used since the advantage of discovering imaging biomarkers, which can identify the genomics without biopsy, so that especially required for hard-to-reach cancer like GBM. For this study, we analyzed relationship between expression level of immune cells and various clinical magnetic resonance image (MRI) parameters in total 60 GBM patients. This retrospective human study was approved by the institutional review board of Seoul National University Hospital. Fourteen immune cell markers (e.g. CD11b, CD68, CSF1R, CD163, CD33, CD123, CD83, CD63, CD49d and CD117 for myeloid cells, and CD4, CD3e, CD25 and CD8 for lymphoid cells) were selected for analysis of RNA level using quantitative RT-PCR. For MRI analysis, various MR parameters from fluid-attenuated inversion recovery (FLAIR), contrast-enhanced T1 weighted image (CE T1WI), dynamic susceptibility contrast (DSC) and diffusion weighted image (DWI) were used. In addition, Progression-free survival (PFS) associated with interested mRNA was performed by Kaplan-Meier survival analysis. In results, CD163 which marks tumor associated macrophages/microglia (TAMs) showed the highest expression level in GBM patients. CD68 (TAMs), CSF1R (TAMs), CD33 (Myeloid-derived suppressor cell) and CD4 (Helper T cell, Regulatory T cell) levels were highly positively correlated with normalized cerebral blood volume (nCBV) values, while CD3e (Helper T cell, Cytotoxic T cell) and CD49d showed significantly negative correlation with apparent diffusion coefficient (ADC) values. Moreover, regardless of IDH1, MGMT promoter, ATRX and 1p/19q mutant status, CD49d was revealed as one independent factor for PFS of GBM patients by Cox proportional-hazards regression analysis. In conclusion, expression level of CD49d correlated with ADC can be considered as a candidate biomarker to predict progression of GBM patients.
P3.01-071 Randomized Phase 1b/3 Study of Erlotinib + Ramucirumab in Untreated EGFR Mutation-Positive Stage IV NSCLC: Phase 1b Outcomes
Authors: K. Nakagawa, E. Garon, L. Paz-Ares, S. Ponce, J. Corral Jaime, O. Juan Vidal, E. Nadal, K. Kiura, K. Park, R. Widau, E. Alexandris, S. He, P. Lee, M. Reck
Journal: Journal of Thoracic Oncology (2017)
GENE-44. CHROMOTHRIPSIS LEADS TO CHROMOSOMAL REARRANGEMENTS AND GENE FUSIONS IN PRIMARY GLIOBLASTOMAS
Authors: Audrey Rousseau, Anne Coutolleau, Philippe Menei, Philippe Guardiola, Blandine Boisselier
Journal: Neuro-Oncology (2017)

Glioblastoma (GB) is the most frequent and lethal form of diffuse glioma. GB displays chromosome instability and recurrent somatic copy number alterations. Recently, chromothripsis (CT) has been identified in cancer patients. It is a cataclysmic event in which a single or a few chromosomes (chr) are shattered and then randomly reassembled in a derivative chr, sometimes with additional double-minute chr and gene amplification. It may also disrupt tumor suppressor genes or lead to oncogenic fusion genes. Such genes may represent potential therapeutic targets. CT and consequent gene fusions have not been well described in large GB cohorts. We used pan-genomic single nucleotide polymorphism (SNP) arrays (CytoSNP 850K, Illumina) to identify CT patterns in 183 primary GB. We performed RNA sequencing in 19 cases with CT. We validated the gene fusions detected by RT-PCR and Sanger sequencing. CT occurred in 38.3 % of GB (70/183 cases) and mostly affected chrs 7, 9 and 12, with amplification of oncogenes (e.g., EGFR, MDM2/CDK4), and homozygous deletion of tumor suppressor genes (e.g., CDKN2A). We detected and validated 26 gene fusions (17 in-frame and 9 out-of-frame) in 15 of the 19 cases RNA-sequenced. The 17 in-frame fusions (from 11 patients) were all located in CT regions. They were intrachromosomal events involving nearby genes. We identified novel gene fusions implicating (potential) oncogenes such as ACVR1, MDM2, HMGA2, EGFR, MET, and MAPK4. Some of these fusions may be recurring events like the FGFR3-TACC3 fusion. Additional GB cases with CT are being RNA-sequenced. CT is a frequent event in GB. It recurrently targets key genes in gliomagenesis/tumor progression and leads to gene fusions in GB. Thorough analysis of genomic regions affected by CT will most likely lead to the identification of novel fusion genes, potential therapeutic targets in this fatal disease.
MA 15.12 Expanding the Lung Small RNA Transcriptome: Discovery of Unannotated microRNAs with Roles in Development and Tumorigenesis
Authors: B. Minatel, V. Martinez, A. Sage, E. Marshall, K. Ng, C. Anderson, D. Becker-Santos, W. Robinson, I. Jurisica, W. Lam
Journal: Journal of Thoracic Oncology (2017)
TMIC-48. REGULATION OF THE PROTEASE ADAM17 BY EXTRACELLULAR SIGNALS DRIVES PRO-TUMORAL PROGRAMS IN GLIOBLASTOMA CELLS AND THEIR MICROENVIRONMENT.
Authors: Mohan Sobhana Nandhu, Vivek Bhaskaran, Bin Hu, Mariano Viapiano
Journal: Neuro-Oncology (2017)

The cell-surface metalloprotease ADAM17/TACE regulates multiple signaling cascades, such as Notch and NFkB, which are critical for glioblastoma (GBM) growth and invasion. This enzyme is tonically inhibited by the extracellular matrix (ECM)-associated protein TIMP3, but signals that release ADAM17 inhibition have not been described. Fibulin-3 is an ECM protein highly enriched in GBMs that activates Notch and NFkB signaling but does not seem to bind to membrane receptors for these pathways. Therefore, we investigated if fibulin-3 could simultaneously regulate both mechanisms in GBM by activating ADAM17. Using cultured GBM cells we demonstrated that fibulin-3 increases the expression and activity of ADAM17. Activated ADAM17 released membrane-bound TNF-alpha, which activated TNF-alpha receptors and NFkB signaling. At the same time activated ADAM17 increased the cleavage and activity of Notch1 receptor, explaining the ability of fibulin-3 to simultaneously regulate multiple pro-tumoral pathways. Using mixed cultures, ex vivo brain slices, and intracranial tumor models, we demonstrated that fibulin-3 secreted by GBM cells also increases Notch activity in endothelial cells to enhance angiogenesis, and NFkB activity in astroglial cells to facilitate tumor invasion. Mechanistically, fibulin-3 regulated ADAM17 by competition with TIMP3; accordingly, downregulation of fibulin-3 reduced ADAM17 activity and silenced Notch and NFkB signaling in GBM cells. We identified an N-terminal sequence of fibulin-3 that was critical to capture TIMP3 and activate ADAM17. An antibody against this sequence blocked fibulin-3 and downregulated ADAM17 activity in GBMs, reducing tumor growth. In conclusion, ADAM17 is critical to drive pro-tumoral programs in GBMs, and is in turn regulated by competition of stimulatory (fibulin-3) and inhibitory (TIMP3) signals in the tumor ECM. Disrupting the fibulin-3/ADAM17 axis could inhibit multiple pro-tumoral mechanisms and cause widespread anti-tumor effects.
P3.09-006 Preoperative Six-Minute Walk Distance and Desaturation in Patients with Malignant Pleural Mesothelioma
Authors: M. Nagaya, S. Ito, T. Fukui, T. Inoue, Y. Mizuno, K. Kawaguchi, S. Nakamura, Y. Nishida, Y. Hasegawa, K. Yokoi
Journal: Journal of Thoracic Oncology (2017)
MA 01.05 Activity and Safety of the Combination of PM01183 and Doxorubicin in Relapsed SCLC. Final Results of a Phase Ib Trial
Authors: E. Calvo, M. Forster, V. Moreno, M.E. Olmedo, M.P. Lopez Criado, J. Lopez-Vilariño, C. Kahatt, A. Soto-Matos
Journal: Journal of Thoracic Oncology (2017)
MA 17.07 Veliparib in Combination with Paclitaxel/Carboplatin (P/C)-Based Chemoradiotherapy (CRT) in Patients with Stage III NSCLC
Authors: T. Stinchcombe, D. Kozono, J. Salama, J. Bogart, W. Petty, M. Guarino, L. Bazhenova, J. Larner, J. Weiss, T. Dipetrillo, S. Feigenberg, T. Xu, B. Hu, S. Nuthalapati, L. Rosenwinkel, L. Bensman, E. Johnson, M. Mckee, E. Vokes
Journal: Journal of Thoracic Oncology (2017)